Quantitative Assessments and Clinical Outcomes in HER2 Equivocal 2018 ASCO/CAP ISH Group 4 Breast Cancer

npj Breast Cancer - United Kingdom
doi 10.1038/s41523-019-0122-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines

JAMA Oncology
Cancer ResearchOncology
2019English

Assessment of Dual-Probe Her-2 Fluorescent in Situ Hybridization in Breast Cancer by the 2013 ASCO/CAP Guidelines Produces More Equivocal Results Than That by the 2007 ASCO/CAP Guidelines

Breast Cancer Research and Treatment
Cancer ResearchOncology
2016English

HER2-ASCO-Guidelines

Der Pathologe
Forensic MedicinePathology
2010English

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Oncotarget
Oncology
2017English

ASCO 2015: Highlights in Breast Cancer

Memo - Magazine of European Medical Oncology
OncologyHematology
2015English

Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma

Journal of Pathology and Translational Medicine
Forensic MedicinePathologyHistology
2016English

Breast Cancer News From ASCO 2013

Breast Care
SurgeryOncology
2013English

Necessity of in Situ Hybridization Test of Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Patients With Equivocal HER2 Immunohistochemistry Results

Journal of Breast Disease
2018English

Clinical Significance of Quantitative HER2 Gene Amplification as Related to Its Predictive Value in Breast Cancer Patients in Neoadjuvant Setting

OncoTargets and Therapy
OncologyPharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy